133 related articles for article (PubMed ID: 25445160)
1. Predictors of early stages of histological progression of branch duct IPMN.
Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Kijima Y; Ishigami S; Ueno S; Shinchi H; Natsugoe S
Langenbecks Arch Surg; 2015 Jan; 400(1):49-56. PubMed ID: 25445160
[TBL] [Abstract][Full Text] [Related]
2. MUC2 expression and prevalence of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous neoplasm of the pancreas.
Masuda A; Arisaka Y; Hara S; Matsumoto I; Takenaka M; Sakai A; Shiomi H; Matsuki N; Sugimoto M; Fujita T; Hayakumo T; Ku Y; Ogino S; Azuma T; Kutsumi H
Pancreatology; 2013; 13(6):583-8. PubMed ID: 24280573
[TBL] [Abstract][Full Text] [Related]
3. A large multicenter study of recurrence after surgical resection of branch-duct intraductal papillary mucinous neoplasm of the pancreas.
Yan L; Siddiqui AA; Laique SN; Saumoy M; Kahaleh M; Yoo J; Kalra A; Mathew A; Sterling J; Rao R; Lieberman M; Cosgrove N; Sharaiha RZ
Minerva Gastroenterol Dietol; 2017 Mar; 63(1):50-54. PubMed ID: 27824244
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for postoperative recurrence of intraductal papillary mucinous neoplasms of the pancreas based on a long-term follow-up study: proposals for follow-up strategies.
Yogi T; Hijioka S; Imaoka H; Mizuno N; Hara K; Tajika M; Tanaka T; Ishihara M; Shimizu Y; Hosoda W; Yatabe Y; Niwa Y; Yoshimura K; Bhatia V; Fujita J; Yamao K
J Hepatobiliary Pancreat Sci; 2015 Oct; 22(10):757-65. PubMed ID: 26148131
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk.
Fritz S; Klauss M; Bergmann F; Strobel O; Schneider L; Werner J; Hackert T; Büchler MW
Ann Surg; 2014 Nov; 260(5):848-55; discussion 855-6. PubMed ID: 25379856
[TBL] [Abstract][Full Text] [Related]
6. Invasive, mixed-type intraductal papillary mucinous neoplasm: superior prognosis compared to invasive main-duct intraductal papillary mucinous neoplasm.
Ceppa EP; Roch AM; Cioffi JL; Sharma N; Easler JJ; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
Surgery; 2015 Oct; 158(4):937-44; discussion 944-5. PubMed ID: 26173683
[TBL] [Abstract][Full Text] [Related]
7. Clinical implication of serum carcinoembryonic antigen and carbohydrate antigen 19-9 for the prediction of malignancy in intraductal papillary mucinous neoplasm of pancreas.
Kim JR; Jang JY; Kang MJ; Park T; Lee SY; Jung W; Chang J; Shin Y; Han Y; Kim SW
J Hepatobiliary Pancreat Sci; 2015 Sep; 22(9):699-707. PubMed ID: 26178866
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Indications for Limited Surgery of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
Kimura K; Amano R; Ymazoe S; Ohira G; Nishio K; Hirakawa K; Ohira M
World J Surg; 2017 May; 41(5):1358-1365. PubMed ID: 27882420
[TBL] [Abstract][Full Text] [Related]
9. Management of intraductal papillary-mucinous neoplasm of the pancreas: treatment strategy based on morphologic classification.
Serikawa M; Sasaki T; Fujimoto Y; Kuwahara K; Chayama K
J Clin Gastroenterol; 2006 Oct; 40(9):856-62. PubMed ID: 17016145
[TBL] [Abstract][Full Text] [Related]
10. Preoperative histological subtype classification of intraductal papillary mucinous neoplasms (IPMN) by pancreatic juice cytology with MUC stain.
Hara T; Ikebe D; Odaka A; Sudo K; Nakamura K; Yamamoto H; Itami M; Hirata T; Kashimura J; Yamaguchi T
Ann Surg; 2013 Jun; 257(6):1103-11. PubMed ID: 23364699
[TBL] [Abstract][Full Text] [Related]
11. Fate of Patients With Intraductal Papillary Mucinous Neoplasms of Pancreas After Resection According to the Pathology and Margin Status: Continuously Increasing Risk of Recurrence Even After Curative Resection Suggesting Necessity of Lifetime Surveillance.
Kim HS; Han Y; Kang JS; Choi YJ; Byun Y; Kim H; Lee KB; Kim H; Kwon W; Jang JY
Ann Surg; 2022 Oct; 276(4):e231-e238. PubMed ID: 32941274
[TBL] [Abstract][Full Text] [Related]
12. High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Cancer.
Majumder S; Philip NA; Singh Nagpal SJ; Takahashi N; Mara KC; Kendrick ML; Smyrk TC; Zhang L; Levy MJ; Gleeson FC; Petersen BT; Pearson RK; Topazian MD; Vege SS; Chari ST
Am J Gastroenterol; 2019 Mar; 114(3):524-529. PubMed ID: 30413822
[TBL] [Abstract][Full Text] [Related]
13. Preoperative evaluation of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological, and pathological analysis of 123 cases.
Nara S; Onaya H; Hiraoka N; Shimada K; Sano T; Sakamoto Y; Esaki M; Kosuge T
Pancreas; 2009 Jan; 38(1):8-16. PubMed ID: 18665010
[TBL] [Abstract][Full Text] [Related]
14. Malignant potential and specific characteristics of pure main duct type intraductal papillary mucinous neoplasm.
Fujita Y; Hirono S; Kawai M; Okada KI; Miyazawa M; Kitahata Y; Ueno M; Hayami S; Kobayashi R; Yanagisawa A; Yamaue H
Eur J Surg Oncol; 2022 May; 48(5):1054-1061. PubMed ID: 34933794
[TBL] [Abstract][Full Text] [Related]
15. Importance of each high-risk stigmata and worrisome features as a predictor of high-grade dysplasia in intraductal papillary mucinous neoplasms of the pancreas.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Pancreatology; 2020 Jul; 20(5):895-901. PubMed ID: 32624417
[TBL] [Abstract][Full Text] [Related]
16. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic study of the MIB-1 labeling index (Ki67) and postoperative prognosis for intraductal papillary mucinous neoplasms and ordinary ductal adenocarcinoma.
Takeshita A; Kimura W; Hirai I; Takasu N; Moriya T; Tezuka K; Watanabe T
Pancreas; 2012 Jan; 41(1):114-20. PubMed ID: 22143341
[TBL] [Abstract][Full Text] [Related]
18. Differential diagnosis of benign and malignant branch duct intraductal papillary mucinous neoplasm using contrast-enhanced endoscopic ultrasonography.
Harima H; Kaino S; Shinoda S; Kawano M; Suenaga S; Sakaida I
World J Gastroenterol; 2015 May; 21(20):6252-60. PubMed ID: 26034360
[TBL] [Abstract][Full Text] [Related]
19. The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression.
Roch AM; Ceppa EP; Al-Haddad MA; DeWitt JM; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
Ann Surg; 2014 Oct; 260(4):680-8; discussion 688-90. PubMed ID: 25203885
[TBL] [Abstract][Full Text] [Related]
20. Thirty years of experience with intraductal papillary mucinous neoplasm of the pancreas: from discovery to international consensus.
Tanaka M
Digestion; 2014; 90(4):265-72. PubMed ID: 25591885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
